QUALIFYING THERAPEUTIC DISCOVERY PROJECT GRANT	9 Months Ended
Aug. 31, 2011
Qualifying Therapeutic Discovery Project Grant [Abstract]
Qualifying Therapeutic Discovery Project Grant [Text Block]	NOTE 12. QUALIFYING THERAPEUTIC DISCOVERY PROJECT GRANT On October 29, 2010, the Company received notification from the Department of Treasury that it had been awarded a total cash grant of $733,437 under the Qualifying Therapeutic Discovery Project (“QTDP”) program. The QTDP program was created by Congress as part of the Patient Protection and Affordable Care Act, and provides a grant or tax credit equal to 50% of qualified investment for the Company’s fiscal years ending November 30, 2010 and 2011. Of the total grant, $430,335 relates to qualifying expenses incurred during the year ended November 30, 2010 and the remainder of $303,102 will be received and recognized during the year ending November 30, 2011. For the year ended November 30, 2010, the Company recognized $430,335 as grant revenue under “other income” in the consolidated statement of operations. Of the amount that was recognized in the year ended November 30, 2010, $399,360 was received in cash during that fiscal year and the balance of $30,975 was collected during the three months ended February 28, 2011. For the year ending November 30, 2011, the grant revenue will be recognized as other income during the period in which the corresponding expenses are incurred. During the three months and nine months ended August 31, 2011, management of the Company has identified $73,715 and $303,102, respectively, of qualifying expense and recognized an equal amount of grant revenue. The funds were granted in connection with the Company’s projects MCT-465 and MCT-475 drug development programs for the treatment of cancer and MCT-125 drug development for the treatment of fatigue in multiple sclerosis patients.

NOTE 12. QUALIFYING THERAPEUTIC DISCOVERY PROJECT GRANT

On October 29, 2010, the Company received notification from the Department of Treasury that it had been awarded a total cash grant of $733,437 under the Qualifying Therapeutic Discovery Project (“QTDP”) program. The QTDP program was created by Congress as part of the Patient Protection and Affordable Care Act, and provides a grant or tax credit equal to 50% of qualified investment for the Company’s fiscal years ending November 30, 2010 and 2011. Of the total grant, $430,335 relates to qualifying expenses incurred during the year ended November 30, 2010 and the remainder of $303,102 will be received and recognized during the year ending November 30, 2011. For the year ended November 30, 2010, the Company recognized $430,335 as grant revenue under “other income” in the consolidated statement of operations. Of the amount that was recognized in the year ended November 30, 2010, $399,360 was received in cash during that fiscal year and the balance of $30,975 was collected during the three months ended February 28, 2011. For the year ending November 30, 2011, the grant revenue will be recognized as other income during the period in which the corresponding expenses are incurred. During the three months and nine months ended August 31, 2011, management of the Company has identified $73,715 and $303,102, respectively, of qualifying expense and recognized an equal amount of grant revenue.

The funds were granted in connection with the Company’s projects MCT-465 and MCT-475 drug development programs for the treatment of cancer and MCT-125 drug development for the treatment of fatigue in multiple sclerosis patients.